130
Views
2
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study

, &
Pages 3097-3107 | Published online: 16 Jul 2021

References

  • Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802–812. doi:10.1016/j.jtos.2017.08.003
  • McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016;14(2):144–167. doi:10.1016/j.jtos.2015.11.002
  • Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102–6.
  • Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379–387. doi:10.1097/ICO.0b013e3181f7f363
  • Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II Sex, Gender, and Hormones Report. Ocul Surf. 2017;15(3):284–333.
  • Chen X, Wu H, Wei W. Advances in the diagnosis and treatment of Sjogren’s syndrome. Clin Rheumatol. 2018;37(7):1743–1749. doi:10.1007/s10067-018-4153-8
  • Fox RI. Sjögren’s syndrome. Lancet. 2005;366(9482):321–331. doi:10.1016/S0140-6736(05)66990-5
  • Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365.
  • Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
  • Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.
  • Thulasi P, Djalilian AR. Update in current diagnostics and therapeutics of dry eye disease. Ophthalmology. 2017;124(11S):S27–S33. doi:10.1016/j.ophtha.2017.07.022
  • Al-Saedi Z, Zimmerman A, Bachu RD, et al. Dry eye disease: present challenges in the management and future trends. Curr Pharm Des. 2016;22(28):4470–4490. doi:10.2174/1381612822666160614012634
  • Kyei S, Dzasimatu SK, Asiedu K, Ayerakwah PA. Association between dry eye symptoms and signs. J Curr Ophthalmol. 2018;30(4):321–325. doi:10.1016/j.joco.2018.05.002
  • Bron AJ, Tomlinson A, Foulks GN, et al. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014;12(2 Suppl):S1–31.
  • Yazdanpanah G, Jabbehdari S, Djalilian AR. Limbal and corneal epithelial homeostasis. Curr Opin Ophthalmol. 2017;28(4):348–354. doi:10.1097/ICU.0000000000000378
  • Gipson IK. Goblet cells of the conjunctiva: a review of recent findings. Prog Retin Eye Res. 2016;54:49–63. doi:10.1016/j.preteyeres.2016.04.005
  • Ablamowicz AF, Nichols JJ. Ocular surface membrane-associated mucins. Ocul Surf. 2016;14(3):331–341. doi:10.1016/j.jtos.2016.03.003
  • Guzman-Aranguez A, Argüeso P. Structure and biological roles of mucin-type O-glycans at the ocular surface. Ocul Surf. 2010;8(1):8–17. doi:10.1016/S1542-0124(12)70213-6
  • Hori Y. Secreted mucins on the ocular surface. Invest Ophthalmol Vis Sci. 2018;59(14):DES151–DES156. doi:10.1167/iovs.17-23623
  • Nabi IR, Shankar J, Dennis JW. The galectin lattice at a glance. J Cell Sci. 2015;128(13):2213–2219. doi:10.1242/jcs.151159
  • Ahmad N, Gabius HJ, André S, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem. 2004;279(12):10841–10847. doi:10.1074/jbc.M312834200
  • Uchino Y, Mauris J, Woodward AM, et al. Alteration of galectin-3 in tears of patients with dry eye disease. Am J Ophthalmol. 2015;159(6):1027–1035.e3. doi:10.1016/j.ajo.2015.02.008
  • Uchino Y. The ocular surface glycocalyx and its alteration in dry eye disease: a review. Invest Ophthalmol Vis Sci. 2018;59(14):DES157–DES162. doi:10.1167/iovs.17-23756
  • Baudouin C, Rolando M, Benitez Del Castillo JM, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res. 2018;S1350-9462(18):30062–30064.
  • Gipson IK, Hori Y, Argüeso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf. 2004;2(2):131–148. doi:10.1016/S1542-0124(12)70149-0
  • Villatoro AJ, Fernández V, Claros S, et al. Regenerative therapies in dry eye disease: from growth factors to cell therapy. Int J Mol Sci. 2017;18(11):E2264. doi:10.3390/ijms18112264
  • Drew VJ, Tseng CL, Seghatchian J, Burnouf T. Reflections on dry eye syndrome treatment: therapeutic role of blood products. Front Med (Lausanne). 2018;23(5):33. doi:10.3389/fmed.2018.00033
  • Azari AA, Rapuano CJ. Autologous serum eye drops for the treatment of ocular surface disease. Eye Contact Lens. 2015;41(3):133–140. doi:10.1097/ICL.0000000000000104
  • Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol. 2018;18(12):1105–1112. doi:10.2147/OPTH.S165553
  • Sacchetti M, Rama P, Bruscolini A, Lambiase A. Limbal stem cell transplantation: clinical results, limits, and perspectives. Stem Cells Int. 2018;11(2018):8086269.
  • Dong Y, Peng H, Lavker RM. Emerging therapeutic strategies for limbal stem cell deficiency. J Ophthalmol. 2018;27(2018):7894647.
  • Borroni D, Wowra B, Romano V, et al. Simple limbal epithelial transplantation: a review on current approach and future directions. Surv Ophthalmol. 2018;63(6):869–874. doi:10.1016/j.survophthal.2018.05.003
  • Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm585403.pdf. Accessed June 30, 2019.
  • Ngo W, Situ P, Keir N, More. Psychometric properties and validation of the standard patient evaluation of eye dryness questionnaire. Cornea. 2013;32(9):1204–1210. doi:10.1097/ICO.0b013e318294b0c0
  • Rasch AK. Analysis of the standard patient evaluation of eye dryness questionnaire. Eye Contact Lens. 2017;43(6):394–398. doi:10.1097/ICL.0000000000000288
  • Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615–621. doi:10.1001/archopht.118.5.615
  • McMonnies CW. Measurement of symptoms pre- and post-treatment of dry eye syndromes. Optom Vis Sci. 2016;93(11):1431–1437. doi:10.1097/OPX.0000000000000965
  • UNC Dry Eye Management Scale©. Chapel Hill: The University of North Carolina; 2013.
  • Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;28(2):CD009327.
  • Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015;16(9):1719–1730. doi:10.2147/OPTH.S89700
  • Gomes JAP, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: a review. Ocul Surf. 2018;17:9–19.
  • Dohlman TH, Ciralsky JB, Lai EC. Tear film assessments for the diagnosis of dry eye. Curr Opin Allergy Clin Immunol. 2016;16(5):487–491. doi:10.1097/ACI.0000000000000307